Ken Griffin Amphastar Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

13 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2025 Nov 14, 2025	SELL	$20.62 - $30.81 $65,984 - $98,592	-3,200 Reduced 17.49%	15,100 $402,000
Q2 2025 Aug 14, 2025	SELL	$22.96 - $28.29 $57,400 - $70,725	-2,500 Reduced 12.02%	18,300 $420,000
Q1 2025 May 15, 2025	BUY	$26.24 - $38.48 $225,664 - $330,928	8,600 Added 70.49%	20,800 $602,000
Q4 2024 Feb 14, 2025	SELL	$36.84 - $53.4 $456,816 - $662,160	-12,400 Reduced 50.41%	12,200 $452,000
Q3 2024 Nov 14, 2024	BUY	$36.99 - $50.09 $636,228 - $861,548	17,200 Added 232.43%	24,600 $1.19 Million
Q2 2024 Aug 14, 2024	SELL	$38.65 - $43.48 $289,875 - $326,100	-7,500 Reduced 50.34%	7,400 $296,000
Q1 2024 May 15, 2024	BUY	$42.85 - $63.45 $154,260 - $228,420	3,600 Added 31.86%	14,900 $654,000
Q4 2023 Feb 14, 2024	BUY	$44.49 - $62.93 $93,429 - $132,153	2,100 Added 22.83%	11,300 $698,000
Q3 2023 Nov 14, 2023	BUY	$45.51 - $65.0 $104,673 - $149,500	2,300 Added 33.33%	9,200 $423,000
Q2 2023 Aug 14, 2023	BUY	$35.77 - $58.38 $42,924 - $70,056	1,200 Added 21.05%	6,900 $396,000
Q1 2023 May 15, 2023	SELL	$27.99 - $37.92 $67,176 - $91,008	-2,400 Reduced 29.63%	5,700 $213,000
Q4 2022 Feb 14, 2023	SELL	$27.93 - $31.27 $365,883 - $409,637	-13,100 Reduced 61.79%	8,100 $226,000
Q3 2022 Nov 14, 2022	SELL	$27.56 - $37.75 $336,232 - $460,550	-12,200 Reduced 36.53%	21,200 $596,000

260

33.5M

73.4K

12.6K

Ticker AMPH
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,015,200
Market Cap $1.28B
Description
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-count...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.